Allscripts Healthcare Stock
Your prediction
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allscripts Healthcare | - | 11.111% | 11.111% | -42.857% | 11.111% | -74.026% | -70.588% |
| Simulations Plus | -4.110% | -17.045% | -5.195% | -60.541% | -5.195% | -60.541% | -77.538% |
| MicroVision Inc | -3.380% | -4.883% | -8.256% | -55.131% | -8.256% | -74.418% | -88.779% |
| Fonar Corp. New | 0.000% | -1.274% | -0.641% | 1.974% | -0.641% | -6.627% | 5.442% |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at TD Cowen from $26.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat